成人胆汁淤积性肝病谱中ABCB4(MDR3)基因变异
本文综述了ABCB4基因变异导致ABCB4缺陷的疾病谱,范围从进行性家族性胆汁淤积症3型到低磷脂相关胆石症、妊娠期肝内胆汁淤积症或药物性肝损伤。全基因组测序显示ABCB4变异与胆石病、胆囊和胆管癌、肝硬化或肝功能指标升高发生率增加相关。诊断基于临床表现、血清生物标志物、影像技术、肝组织学与基因检测,但基因型-表型相关性目前仍缺乏。
要点
- ABCB4基因变异可导致从进行性家族性胆汁淤积症3型到低磷脂相关胆石症等疾病谱。
- 全基因组测序显示ABCB4变异与胆石病、胆囊和胆管癌、肝硬化或肝功能指标升高相关。
- 熊去氧胆酸是最常用药物治疗,但疗效尚待大型对照临床研究证实。
核心结论
- ABCB4缺陷所致疾病谱广泛,从进行性家族性胆汁淤积症3型到低磷脂相关胆石症、妊娠期肝内胆汁淤积症或药物性肝损伤。
- 全基因组测序显示ABCB4变异与胆石病、胆囊和胆管癌、肝硬化或肝功能指标升高发生率增加相关。
- 熊去氧胆酸是最常用药物治疗,但疗效尚待大型对照临床研究证实。
- 肝移植仍是肝硬化终末期肝病或难治性瘙痒患者的最后且常为唯一的治疗选择。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- ABCB4基因位于7号染色体,编码ABCB4蛋白(别名多药耐药蛋白3[MDR3]),为肝细胞毛细胆管膜上的P-糖蛋白,功能是将磷脂转运至胆汁。
- 多种ABCB4变异可导致ABCB4缺陷,临床表型差异大,目前缺乏明确的基因型-表型相关性。
- 诊断基于临床表现、血清生物标志物、影像技术、肝组织学与基因检测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ATP binding cassette subfamily B member 4 (ABCB4) gene on chromosome 7 encodes the ABCB4 protein (alias multidrug resistance protein 3 [MDR3]), a P-glycoprotein in the canalicular membrane of the hepatocytes that acts as a translocator of phospholipids into bile. Several variants in ABCB4 have been shown to cause ABCB4 deficiency, accounting for a disease spectrum ranging from progressive familial cholestasis type 3 to less severe conditions like low phospholipid-associated cholelithiasis, intrahepatic cholestasis of pregnancy or drug-induced liver injury. Furthermore, whole genome sequencing has shown that ABCB4 variants are associated with an increased incidence of gallstone disease, gallbladder and bile duct carcinoma, liver cirrhosis or elevated liver function tests. Diagnosis of ABCB4 deficiency-related diseases is based on clinical presentation, serum biomarkers, imaging techniques, liver histology and genetic testing. Nevertheless, the clinical presentation can vary widely and clear genotype-phenotype correlations are currently lacking. Ursodeoxycholic acid is the most commonly used medical treatment, but its efficacy has yet to be proven in large controlled clinical studies. Future pharmacological options may include stimulation/restoration of residual function by chaperones (e.g. 4-phenyl butyric acid, curcumin) or induction of ABCB4 transcription by FXR (farnesoid X receptor) agonists or PPARα (peroxisome proliferator-activated receptor-α)-ligands/fibrates. Orthotopic liver transplantation remains the last and often only therapeutic option in cirrhotic patients with end-stage liver disease or patients with intractable pruritus.
引用
- Stättermayer AF, Halilbasic E, Wrba F, et al. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. J Hepatol. 2020. PMID: 32376413. doi:10.1016/j.jhep.2020.04.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。